Optimal timing of influenza vaccination among patients with acute myocardial infarction – Findings from the IAMI trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Optimal timing of influenza vaccination among patients with acute myocardial infarction – Findings from the IAMI trial. / Akhtar, Zubair; Götberg, Matthias; Erlinge, David; Christiansen, Evald H.; Oldroyd, Keith G.; Motovska, Zuzana; Erglis, Andrejs; Hlinomaz, Ota; Jakobsen, Lars; Engstrøm, Thomas; Jensen, Lisette O.; Fallesen, Christian O.; Jensen, Svend E.; Angerås, Oskar; Calais, Fredrik; Kåregren, Amra; Lauermann, Jörg; Mokhtari, Arash; Nilsson, Johan; Persson, Jonas; Islam, Abu K.M.M.; Rahman, Afzalur; Malik, Fazila; Choudhury, Sohel; Collier, Timothy; Pocock, Stuart J.; Pernow, John; MacIntyre, Chandini R.; Fröbert, Ole.
I: Vaccine, Bind 41, Nr. 48, 2023, s. 7159-7165.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Optimal timing of influenza vaccination among patients with acute myocardial infarction – Findings from the IAMI trial
AU - Akhtar, Zubair
AU - Götberg, Matthias
AU - Erlinge, David
AU - Christiansen, Evald H.
AU - Oldroyd, Keith G.
AU - Motovska, Zuzana
AU - Erglis, Andrejs
AU - Hlinomaz, Ota
AU - Jakobsen, Lars
AU - Engstrøm, Thomas
AU - Jensen, Lisette O.
AU - Fallesen, Christian O.
AU - Jensen, Svend E.
AU - Angerås, Oskar
AU - Calais, Fredrik
AU - Kåregren, Amra
AU - Lauermann, Jörg
AU - Mokhtari, Arash
AU - Nilsson, Johan
AU - Persson, Jonas
AU - Islam, Abu K.M.M.
AU - Rahman, Afzalur
AU - Malik, Fazila
AU - Choudhury, Sohel
AU - Collier, Timothy
AU - Pocock, Stuart J.
AU - Pernow, John
AU - MacIntyre, Chandini R.
AU - Fröbert, Ole
N1 - Publisher Copyright: © 2023 The Authors
PY - 2023
Y1 - 2023
N2 - Influenza vaccination reduces the risk of adverse cardiovascular events. The IAMI trial randomly assigned 2571 patients with acute myocardial infarction (AMI) to receive influenza vaccine or saline placebo during their index hospital admission. It was conducted at 30 centers in 8 countries from October 1, 2016 to March 1, 2020. In this post-hoc exploratory sub-study, we compare the trial outcomes in patients receiving early season vaccination (n = 1188) and late season vaccination (n = 1344). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), or stent thrombosis at 12 months. The cumulative incidence of the primary and key secondary endpoints by randomized treatment and early or late vaccination was estimated using the Kaplan-Meier method. In the early vaccinated group, the primary composite endpoint occurred in 36 participants (6.0%) assigned to influenza vaccine and 49 (8.4%) assigned to placebo (HR 0.69; 95% CI 0.45 to 1.07), compared to 31 participants (4.7%) assigned to influenza vaccine and 42 (6.2%) assigned to placebo (HR 0.74; 95% CI 0.47 to 1.18) in the late vaccinated group (P = 0.848 for interaction on HR scale at 1 year). We observed similar estimates for the key secondary endpoints of all-cause death and CV death. There was no statistically significant difference in vaccine effectiveness against adverse cardiovascular events by timing of vaccination. The effect of vaccination on all-cause death at one year was more pronounced in the group receiving early vaccination (HR 0.50; 95% CI, 0.29 to 0.86) compared late vaccination group (HR 0.75; 35% CI, 0.40 to 1.40) but there was no statistically significant difference between these groups (Interaction P = 0.335). In conclusion, there is insufficient evidence from the trial to establish whether there is a difference in efficacy between early and late vaccination but regardless of vaccination timing we strongly recommend influenza vaccination in all patients with cardiovascular diseases.
AB - Influenza vaccination reduces the risk of adverse cardiovascular events. The IAMI trial randomly assigned 2571 patients with acute myocardial infarction (AMI) to receive influenza vaccine or saline placebo during their index hospital admission. It was conducted at 30 centers in 8 countries from October 1, 2016 to March 1, 2020. In this post-hoc exploratory sub-study, we compare the trial outcomes in patients receiving early season vaccination (n = 1188) and late season vaccination (n = 1344). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), or stent thrombosis at 12 months. The cumulative incidence of the primary and key secondary endpoints by randomized treatment and early or late vaccination was estimated using the Kaplan-Meier method. In the early vaccinated group, the primary composite endpoint occurred in 36 participants (6.0%) assigned to influenza vaccine and 49 (8.4%) assigned to placebo (HR 0.69; 95% CI 0.45 to 1.07), compared to 31 participants (4.7%) assigned to influenza vaccine and 42 (6.2%) assigned to placebo (HR 0.74; 95% CI 0.47 to 1.18) in the late vaccinated group (P = 0.848 for interaction on HR scale at 1 year). We observed similar estimates for the key secondary endpoints of all-cause death and CV death. There was no statistically significant difference in vaccine effectiveness against adverse cardiovascular events by timing of vaccination. The effect of vaccination on all-cause death at one year was more pronounced in the group receiving early vaccination (HR 0.50; 95% CI, 0.29 to 0.86) compared late vaccination group (HR 0.75; 35% CI, 0.40 to 1.40) but there was no statistically significant difference between these groups (Interaction P = 0.335). In conclusion, there is insufficient evidence from the trial to establish whether there is a difference in efficacy between early and late vaccination but regardless of vaccination timing we strongly recommend influenza vaccination in all patients with cardiovascular diseases.
KW - Influenza vaccination
KW - Myocardial infarction
KW - Optimal timing
KW - Percutaneous coronary intervention
KW - Vaccine effectiveness
U2 - 10.1016/j.vaccine.2023.10.028
DO - 10.1016/j.vaccine.2023.10.028
M3 - Journal article
C2 - 37925315
AN - SCOPUS:85176266634
VL - 41
SP - 7159
EP - 7165
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 48
ER -
ID: 397245601